Cameron Kluth, MD
Interventional Pain Medicine · Kissimmee, FLNPI 1508245515
Payments from drug & device makers
What this record shows
This record is dominated by grants: $15,000 of the $22,324 with a category attached, or 67.2%. Medtronic accounts for 75.0% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $15,707 and has fallen 87.5% since, to $1,959 in 2025.
Across 287 payments — averaging $77.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$17K
- Boston Scientific$1K
- Nevro Corp.$1K
- Curonix LLC$861
- Collegium Pharmaceutical, Inc.$346
- Biotronik NRO, Inc.$308
- plus $2K from 23 others
What the payments were for
- Grants$15,00067%
- Travel & lodging$9344%
- Food & beverage$6,27628%
- Education$1141%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 84 | $16,734 |
| Boston Scientific | 24 | $1,157 |
| Nevro Corp. | 42 | $1,121 |
| Curonix LLC | 25 | $861 |
| Collegium Pharmaceutical, Inc. | 20 | $346 |
| Biotronik NRO, Inc. | 14 | $308 |
| Abbott | 8 | $250 |
| Scilex Pharmaceuticals Inc. | 15 | $234 |
| Vertos Medical, Inc. | 4 | $161 |
| GRT US Holding, Inc. | 5 | $156 |
| Saluda Medical Americas, Inc. | 5 | $110 |
| Foundation Fusion Solutions, LLC | 5 | $109 |
| AbbVie | 4 | $103 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $99 |
| Valinor Pharma, LLC | 4 | $73 |
| Bioventus LLC | 3 | $68 |
| Tersera Therapeutics LLC | 2 | $53 |
| Amgen | 2 | $46 |
| Stryker | 1 | $46 |
| Averitas Pharma Inc. | 1 | $43 |
| Hikma Pharmaceuticals USA | 2 | $38 |
| Biodelivery Sciences International, Inc. | 3 | $38 |
| SPR Therapeutics, Inc | 2 | $34 |
| Globus Medical | 1 | $33 |
| Nalu Medical, Inc. | 2 | $30 |
| Vertex | 1 | $23 |
| Innovation Technologies Inc | 1 | $17 |
| Johnson & Johnson | 1 | $17 |
| Si-bone, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,324 in reported general payments places this provider in the 85th percentile of 278 interventional pain medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,238 | $37,459 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,286 | $28,858 |
| Pregabalin | 406 | $18,041 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 52 | $8,056 |
| Lidocaine | 89 | $7,307 |
| Gabapentin | 368 | $5,257 |
| MovantikNaloxegol Oxalate | 12 | $4,915 |
| Tizanidine Hcl | 716 | $4,639 |
| Tramadol Hcl | 498 | $4,050 |
| Naloxone Hcl | 62 | $4,042 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 187 | $3,682 |
| Morphine Sulfate | 143 | $3,390 |
| Oxycodone Hcl | 200 | $3,046 |
| Fentanyl | 24 | $2,995 |
| Morphine Sulfate ErMorphine Sulfate | 117 | $2,438 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Morphine Sulfate | $38 | $11,446195 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 278 interventional pain medicine providers in Florida.
Other interventional pain medicine in Kissimmee
- Louis RasoJupiter$1.3M
- Ajay AntonyGainesville$1.1M
- Michael EspositoVero Beach$777K
- Nomen AzeemRiverview$650K
- Stanley GolovacMerritt Island$367K
- Sunil PanchalLutz$363K
- Robert BallPort Charlotte$246K
- Justin MannJacksonville$243K
- Giuseppe PaeseBoca Raton$180K
- Miguel de la GarzaNew Port Richey$138K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.